2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor
Author(s) -
Lumír Hanuš,
Saleh AbuLafi,
Ester Fride,
Aviva Breuer,
Zvi Vogel,
Deborah E. Shalev,
I. M. Kustanovich,
Raphael Mechoulam
Publication year - 2001
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.061029898
Subject(s) - anandamide , endocannabinoid system , chemistry , cannabinoid receptor , cannabinoid , ether , agonist , fatty acid amide hydrolase , endogeny , biochemistry , stereochemistry , receptor , pharmacology , organic chemistry , biology
Two types of endogenous cannabinoid-receptor agonists have been identified thus far. They are the ethanolamides of polyunsaturated fatty acids--arachidonoyl ethanolamide (anandamide) is the best known compound in the amide series--and 2-arachidonoyl glycerol, the only known endocannabinoid in the ester series. We report now an example of a third, ether-type endocannabinoid, 2-arachidonyl glyceryl ether (noladin ether), isolated from porcine brain. The structure of noladin ether was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by comparison with a synthetic sample. It binds to the CB(1) cannabinoid receptor (K(i) = 21.2 +/- 0.5 nM) and causes sedation, hypothermia, intestinal immobility, and mild antinociception in mice. It binds weakly to the CB(2) receptor (K(i) > 3 microM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom